Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.

Cecil Ten CateSandra M H HuijsAnna C H WillemsenRaphael C O S PasmansDaniëlle B P EekersCatharina M L ZegersLinda AckermansJan BeckervordersandforthElisabeth P M van RaakMonique H M E AntenAnn HoebenAlida A PostmaMartinus P G Broen

Published in: Journal of neuro-oncology (2022)

Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma, especially in frail patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, which enables the implementation of adequate intervention strategies.

Keyphrases

newly diagnosed
skeletal muscle
end stage renal disease
randomized controlled trial
ejection fraction
primary care
prognostic factors
optical coherence tomography
community dwelling